Aberrant epigenetic silencing of neuronatin is a frequent event in human osteosarcoma.
Title
Aberrant epigenetic silencing of neuronatin is a frequent event in human osteosarcoma.
Creator
Saeed H; Sinha S; Mella C; Kuerbitz JS; Cales ML; Steele MA; Stanke J; Damron D; Safadi F; Kuerbitz SJ
Publisher
Oncotarget
Date
2020
2020-05
Description
The paternally imprinted neuronatin (NNAT) gene has been identified as a target of aberrant epigenetic silencing in diverse cancers, but no association with pediatric bone cancers has been reported to date. In screening childhood cancers, we identified aberrant CpG island hypermethylation in a majority of osteosarcoma (OS) samples and in 5 of 6 human OS cell lines studied but not in normal bone-derived tissue samples. CpG island hypermethylation was associated with transcriptional silencing in human OS cells, and silencing was reversible upon treatment with
Subject
DNA methylation; neuronatin; osteosarcoma; tumor suppressor genes
Identifier
Rights
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
Format
journalArticle
URL Address
Search for Full-text
Users with a NEOMED Library login can search for full-text journal articles at the following url: https://libraryguides.neomed.edu/home
Pages
1876–1893
Issue
20
Volume
11
NEOMED College
NEOMED College of Medicine
NEOMED College of Pharmacy
NEOMED Department
Department of Anatomy & Neurobiology
Department of Pharmaceutical Sciences
Department of Pediatrics
Update Year & Number
July 2020 List
Affiliated Hospital
Akron Children's Hospital
Citation
Saeed H; Sinha S; Mella C; Kuerbitz JS; Cales ML; Steele MA; Stanke J; Damron D; Safadi F; Kuerbitz SJ, “Aberrant epigenetic silencing of neuronatin is a frequent event in human osteosarcoma.,” NEOMED Bibliography Database, accessed April 28, 2024, https://neomed.omeka.net/items/show/11161.